Longitudinal metabolite changes in huntington's disease during disease onset

Journal of Huntington's Disease

Volumn 3, Issue 4, 2014, Pages 377-386

  Van Den Bogaard, Simon J A ^a   Dumas, Eve M ^a   Teeuwisse, Wouter M ^a   Kan, Hermien E ^a   Webb, Andrew ^a   Van Buchem, Mark A ^a   Roos, Raymund A C ^a   Van Der Grond, Jeroen ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biomarker; Huntington's disease; MRS; NAA; neurodegenerative disorders

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; ASPARTIC ACID; CREATININE; N-ACETYLASPARTATE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR ASSESSMENT; CAG REPEAT; CAUDATE NUCLEUS; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MALE; METABOLITE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONSET AGE; PREFRONTAL CORTEX; PSYCHOLOGIC TEST; PUTAMEN; SIGNAL NOISE RATIO; UNIFIED HUNTINGTON DISEASE RATING SCALE; ANALOGS AND DERIVATIVES; CHEMISTRY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MOLECULAR IMAGING; PROCEDURES;

ADULT; ASPARTIC ACID; CAUDATE NUCLEUS; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MOLECULAR IMAGING; PREFRONTAL CORTEX; PUTAMEN;

EID: 84928703229     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140117     Document Type: Article

References (32)

1. van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, Van der Grond J, Roos RA;TRACK-HDInvestigator Group. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol. 2011;258(3):412-20.
2. van den Bogaard S, Dumas E, van der Grond J, van BM, Roos R. MRI biomarkers in Huntington's disease. Front Biosci. (Elite Ed) 2012;4:1910-25.
3. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, D. Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801.
4. Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington's disease-neuropathology. Handb Clin Neurol. 2011;100: 83-100.
5. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, McDonald M, Beglinger LJ, DuffK, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80.
6. Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971-83.
7. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: From huntingtin functions to potential treatments. Curr Opin Neurol. 2008;21(4):497-503.
8. Ross CA, Tabrizi SJ. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.
9. Sturrock A, Leavitt BR. The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol. 2010;23(4): 243-59.
10. van den Bogaard SJ, Dumas EM, Teeuwisse WM, Kan HE, Webb A, Roos RA, van Buchem MA, Van der Grond J. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol. 2011;258(12):2230-39.
11. Sturrock A, Laule C, Decolongon J, Dar SR, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, MacKay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 2010;75(19):1702-10.
12. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio AA,Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology. 1999;53(4): 806-12.
13. Unschuld PG, Edden RA, Carass A, Liu X, Shanahan M, Wang X, Oishi K, Brandt J, Bassett SS, Redgrave GW, Margolis RL, van Zijl PC, Barker PB, Ross CA. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord. 2012;27(7):895-902.
14. van Oostrom JC, Sijens PE, Roos RA, Leenders KL. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res. 2007;1168:67-71.
15. Gomez-Anson B, Alegret M, Munoz E, Sainz A, Monte GC, Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology. 2007;68(12):906-10.
16. Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, Bryant DJ, Brooks DJ. Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory. Mov Disord. 1996;11(2):167-73.
17. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993;43(12):2689-95.
18. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267-77.
19. Versluis MJ, Kan HE, van Buchem MA,Webb AG. Improved signal to noise in proton spectroscopy of the human calf muscle at 7 T using localized B1 calibration. Magn Reson Med. 2010;63(1):207-11.
20. Schar M, Kozerke S, Fischer SE, Boesiger P. Cardiac SSFP imaging at 3 Tesla. Magn Reson Med. 2004;51(4): 799-806.
21. Tkac I, Gruetter R. Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl Magn Reson. 2005;29(1):139-57.
22. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med. 1999;41(4):649-56.
23. ProvencherSW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-79.
24. Provencher SW. Automatic quantitation of localized in vivo 1Hspectra with LC Model. NMR Biomed. 2001;14(4):260-64.
25. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T. Magn Reson Med. 2009;62(4):868-79.
26. Patenaude B, Smith S, Kennedy D, Jenkinson M. FIRST-FMRIB's integrated registration and segmentation tool. 2007. In Human Brain Mapping Conference.
27. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689-92.
28. Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: Long-term effects 7-10 years after the test. Health Psychol. 2004;23(2):189-97.
29. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Wang C, Stout JC, Ross CA, Aylward E, Carlozzi NE, Queller S; Predict-HD Investigators of the Huntington Study Group. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: Evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22(2):196-207.
30. Bartha R. Effect of signal-to-noise ratio and spectral linewidth on metabolite quantification at 4 T. NMR Biomed. 2007;20(5):512-21.
31. Okada T, Sakamoto S, Nakamoto Y, Kohara N, Senda M. Reproducibility of magnetic resonance spectroscopy in correlation with signal-to-noise ratio. Psychiatry Res. 2007;156(2):169-74.
32. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 2004;17(6):361-81.